Imugene Limited (AU:IMU) has released an update.
Imugene Limited reports notable success in its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy, with three patients achieving complete responses in the treatment of relapsed/refractory diffuse large B cell lymphoma. The trial, which involves patients who had previously undergone multiple treatments, including autologous CAR T therapies, has demonstrated the safety and tolerability of azer-cel. Imugene plans to continue enrolling patients and monitor the durability of the responses, with the Cohort B regimen potentially advancing to FDA Phase 2/3 trials.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
